• Forbion portfolio company VectorY Therapeutics raised €74.5 million ($83.5 million) to advance its clinical and preclinical neurodegenerative disease pipeline.
• New investors included Angelini Ventures, Invest-NL and the European Investment Bank; Forbion participated through its Growth and Ventures strategies.
• Proceeds will fund lead program VTx-002 through the final readout of PIONEER-ALS, a Phase 1/2 study in amyotrophic lateral sclerosis.
• In September 2026, VectorY expanded PIONEER-ALS enrollment from 12 to 36 participants.
• The financing will also support VTx-003 for Huntington’s disease and additional neurodegenerative disease programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forbion Capital Partners Management Services BV published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein.